Neumora Therapeutics, Inc. (NMRA) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 3, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-Q for Q2 FY2026, filed Aug 14, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the NMRA SEC filings page.
This page shows Neumora Therapeutics, Inc. (NMRA) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 4 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Neumora remains a development-stage business: research spending drives large operating losses, while reported net income does not reflect cash economics.
In FY2025, reported net income was$236.9M even as it recorded an operating loss of$241.2M . Operating cash flow was-$206.4M , so the reported profit did not translate into cash from operations and cannot be treated as operating earnings.
No revenue is reported through FY2025, while research and development spending was
Total assets fell from
Financial Health Signals
Neumora Therapeutics, Inc. does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.
Neumora Therapeutics, Inc. passes 2 of 7 computable financial strength tests (2 of the nine could not be computed from available data). 2 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution).
For every $1 of reported earnings, Neumora Therapeutics, Inc. used $0.87 of operating cash (-$206.4M OCF vs $236.9M net income). Earnings that no cash stands behind rest on accounting accruals, which cannot be repeated indefinitely.
Neumora Therapeutics, Inc. reported an operating loss of $241.2M against $2.0M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.
Key Financial Metrics
Earnings & Revenue
Neumora Therapeutics, Inc.'s EBITDA was -$42.2M in Q2 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 21.9% from the same quarter a year earlier. Against the prior quarter it is up 20.2%.
Neumora Therapeutics, Inc. reported -$43.1M in net income in Q2 2026. This represents an increase of 18.3% from the same quarter a year earlier. Against the prior quarter it is up 19.4%.
Neumora Therapeutics, Inc. earned -$0.23 per diluted share (EPS) in Q2 2026. This represents an increase of 30.3% from the same quarter a year earlier. Against the prior quarter it is up 23.3%.
Not reported for Q2 2026.
Cash & Balance Sheet
Neumora Therapeutics, Inc. held $116.8M in cash against $52.9M in long-term debt as of Q2 2026.
Not reported for Q2 2026.
Not reported for Q2 2026.
Margins & Returns
Neumora Therapeutics, Inc.'s ROE was -96.8% in Q2 2026, measuring profit generated per dollar of shareholder equity. This is down 67.9 percentage points from the same quarter a year earlier. Against the prior quarter it is down 21.1 percentage points.
Not reported for Q2 2026.
Not reported for Q2 2026.
Not reported for Q2 2026.
Capital Allocation
Neumora Therapeutics, Inc. invested $29.3M in research and development in Q2 2026. This represents a decrease of 24.4% from the same quarter a year earlier. Against the prior quarter it is down 24.1%.
Not reported for Q2 2026.
Not reported for Q2 2026.
NMRA Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| R&D Expenses | $29.3M-24.4% | $38.6M-26.0% | N/A | $40.5M-33.2% | $38.7M-20.4% | $52.2M+14.0% | N/A | $60.6M+45.7% |
| SG&A Expenses | $12.9M-15.7% | $14.3M-24.1% | N/A | $12.2M-24.0% | $15.3M+0.8% | $18.8M+31.2% | N/A | $16.0M+4.9% |
| Operating Income | -$42.2M+21.9% | -$52.9M+25.5% | N/A | -$57.7M+24.7% | -$54.0M+15.3% | -$70.9M-18.1% | N/A | -$76.6M-34.8% |
| EBITDA | -$42.2M+21.9% | -$52.9M+25.3% | N/A | -$57.7M+24.6% | -$54.0M+15.1% | -$70.8M-18.1% | N/A | -$76.5M-34.9% |
| Interest Expense | $1.4M+364.5% | $1.4M | N/A | $747K | $307K | $0 | N/A | $0 |
| Income Tax | $0-100.0% | $30K-71.4% | N/A | $0-100.0% | $25K-80.0% | $105K | N/A | $53K |
| Net Income | -$43.1M+18.3% | -$53.5M+21.4% | N/A | -$56.8M+21.8% | -$52.7M+10.2% | -$68.0M-26.6% | N/A | -$72.5M-36.8% |
| EPS (Basic) | -$0.23+30.3% | -$0.30+28.6% | -$0.35+5.4% | -$0.35+22.2% | -$0.33+10.8% | -$0.42-23.5% | -$0.37-825.0% | -$0.45+60.5% |
| EPS (Diluted) | -$0.23+30.3% | -$0.30+28.6% | -$0.35+5.4% | -$0.35+22.2% | -$0.33+10.8% | -$0.42-23.5% | -$0.37-825.0% | -$0.45 |
| Diluted Shares (Avg) | 185M+14.5% | 180M+11.4% | N/A | 162M+1.4% | 162M+1.7% | 161M+2.2% | N/A | 160M |
Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit.
NMRA Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $125.2M-44.0% | $153.9M-40.1% | $191.0M-39.7% | $177.8M-49.6% | $223.8M-44.7% | $256.7M-43.0% | $317.0M-36.1% | $352.5M-35.3% |
| Current Assets | $124.9M-44.0% | $153.4M-39.8% | $190.5M-39.3% | $177.1M-49.2% | $222.9M-44.0% | $254.9M-42.4% | $314.1M-34.3% | $348.6M-33.7% |
| Cash & Equivalents | $116.8M-6.2% | $147.1M+15.9% | $182.5M+28.4% | $129.1M-53.2% | $124.5M-17.4% | $126.9M-30.6% | $142.1M-62.0% | $275.7M-33.1% |
| Short-Term Investments | $0-100.0% | $0-100.0% | $0-100.0% | $42.5M-35.3% | $93.1M-57.9% | $122.5M-48.9% | $165.4M+106.9% | $65.6M-32.6% |
| Long-Term Investments | $0 | $0 | $0 | $0 | $0 | $0-100.0% | $0-100.0% | $0-100.0% |
| Total Liabilities | $80.7M+97.2% | $83.2M+193.1% | $87.2M+191.5% | $45.7M+43.6% | $40.9M+76.4% | $28.4M+10.6% | $29.9M+10.3% | $31.8M-0.8% |
| Current Liabilities | $27.8M+31.3% | $30.1M+6.1% | $32.5M+8.6% | $25.8M-18.6% | $21.2M-8.5% | $28.4M+15.3% | $29.9M+19.0% | $31.7M+9.0% |
| Non-Current Liabilities | $53.0M+167.6% | $53.1M | $54.7M+248650.0% | $19.8M+35954.5% | $19.8M+22136.0% | $0-100.0% | $22K-98.9% | $55K-98.1% |
| Long-Term Debt | $52.9M+172.0% | $53.0M | $54.5M | $19.6M | $19.5M | N/A | $0 | N/A |
| Total Equity | $44.5M-75.7% | $70.7M-69.0% | $103.9M-63.8% | $132.2M-58.8% | $182.9M-52.0% | $228.4M-46.2% | $287.1M-38.8% | $320.7M-37.4% |
| Retained Earnings | -$1.3B-19.9% | -$1.2B-21.9% | -$1.2B-25.0% | -$1.1B-26.6% | -$1.1B-30.9% | -$1.0B-34.1% | -$947.2M-34.7% | -$888.4M-49.4% |
Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill.
NMRA Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$39.5M+24.6% | -$46.4M+21.9% | -$48.0M+4.7% | -$46.6M-39.3% | -$52.4M+6.7% | -$59.4M-38.4% | -$50.3M+2.1% | -$33.5M+29.9% |
| Depreciation & Amortization | $7K-63.2% | $8K-94.9% | $9K-94.3% | $23K-85.3% | $19K-88.1% | $157K-0.6% | $157K-5.4% | $156K-9.8% |
| Stock-Based Compensation | $7.2M+0.3% | $7.4M-20.6% | N/A | $6.0M-39.9% | $7.2M-43.9% | $9.3M+26.5% | N/A | $9.9M+54.2% |
| Investing Cash Flow | $0-100.0% | $71K-99.8% | $42.6M+143.2% | $51.3M-67.3% | $30.4M+43.0% | $44.2M+129.4% | -$98.8M-822.4% | $157.0M+559.2% |
| Financing Cash Flow | $9.3M-49.7% | $10.9M | $58.8M+277.4% | -$136K-108.9% | $18.5M+595.4% | $0-100.0% | $15.6M+3337.6% | $1.5M-99.3% |
Not reported in any period shown, so not listed: Capital Expenditures, Free Cash Flow, Dividends Paid, Share Buybacks.
NMRA Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Return on Equity | -96.8%-67.9pp | -75.6%-45.9pp | N/A | -42.9%-20.3pp | -28.8%-13.4pp | -29.8%-17.1pp | N/A | -22.6%-12.3pp |
| Return on Assets | -34.4%-10.8pp | -34.7%-8.3pp | N/A | -31.9%-11.3pp | -23.6%-9.0pp | -26.5%-14.5pp | N/A | -20.6%-10.9pp |
| Current Ratio | 4.50-6.0x | 5.09-3.9x | 5.87-4.6x | 6.85-4.1x | 10.54-6.7x | 8.98-9.0x | 10.51-8.5x | 10.98-7.1x |
| Debt-to-Equity | 1.19+1.1x | 0.75+0.6x | 0.53+0.5x | 0.150.0x | 0.110.0x | 0.12+0.1x | 0.00-0.1x | 0.100.0x |
Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, Asset Turnover, FCF Margin.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| Neumora Therapeutics, Inc. NMRA | FY2025 | N/A | $236.9M | N/A | $93.9M | — |
| Annexon, Inc. ANNX | FY2025 | N/A | -$206.7M | N/A | $794.3M | — |
| Tonix Pharmaceuticals Holding Corp. TNXP | FY2025 | $13.1M | -$124.0M | N/A | $152.8M | 69/100 |
| Vanda Pharmaceuticals Inc. VNDA | FY2025 | $216.1M | -$220.5M | N/A | $279.9M | 35/100 |
| Candel Therapeutics, Inc. CADL | FY2025 | N/A | -$38.2M | N/A | $779.0M | — |
| Atea Pharmaceuticals, Inc. AVIR | FY2025 | N/A | -$158.0M | N/A | $411.5M | — |
Where Neumora Therapeutics, Inc. Ranks
Frequently Asked Questions
Is Neumora Therapeutics, Inc. profitable?
Yes, Neumora Therapeutics, Inc. (NMRA) reported a net income of $236.9M in fiscal year 2025.
What is Neumora Therapeutics, Inc.'s EBITDA?
Neumora Therapeutics, Inc. (NMRA) had EBITDA of -$240.9M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
How much debt does Neumora Therapeutics, Inc. have?
As of fiscal year 2025, Neumora Therapeutics, Inc. (NMRA) had $182.5M in cash and equivalents against $54.5M in long-term debt.
What is Neumora Therapeutics, Inc.'s return on equity (ROE)?
Neumora Therapeutics, Inc. (NMRA) has a return on equity of 228.1% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Neumora Therapeutics, Inc.'s operating cash flow?
Neumora Therapeutics, Inc. (NMRA) recorded an outflow of $206.4M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are Neumora Therapeutics, Inc.'s total assets?
Neumora Therapeutics, Inc. (NMRA) had $191.0M in total assets as of fiscal year 2025, including both current and long-term assets.
How much does Neumora Therapeutics, Inc. spend on research and development?
Neumora Therapeutics, Inc. (NMRA) invested $176.1M in research and development during fiscal year 2025.
What is Neumora Therapeutics, Inc.'s current ratio?
Neumora Therapeutics, Inc. (NMRA) had a current ratio of 5.87 as of fiscal year 2025, which is generally considered healthy.
What is Neumora Therapeutics, Inc.'s debt-to-equity ratio?
Neumora Therapeutics, Inc. (NMRA) had a debt-to-equity ratio of 0.53 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Neumora Therapeutics, Inc.'s return on assets (ROA)?
Neumora Therapeutics, Inc. (NMRA) had a return on assets of 124.0% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Neumora Therapeutics, Inc.'s P/E ratio?
Neumora Therapeutics, Inc. (NMRA) trades at 0.4x earnings, its market capitalization divided by net income of $236.9M net income, FY2025. The market capitalization is $93.9M as of Oct 3, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is Neumora Therapeutics, Inc.'s price-to-sales ratio?
Neumora Therapeutics, Inc. (NMRA) has no price-to-sales ratio at the moment: no revenue reported. The market capitalization is $93.9M as of Oct 3, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
How does Neumora Therapeutics, Inc.'s liquidity compare with its operating cash outflow?
At the end of fiscal year 2025, Neumora Therapeutics, Inc. (NMRA) held $182.5M in cash, cash equivalents and investments, and reported an operating cash outflow of $206.4M over that year. Dividing the one by the other, the reported balance equals about 11 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
What is Neumora Therapeutics, Inc.'s Piotroski F-Score?
Neumora Therapeutics, Inc. (NMRA) has a Piotroski F-Score of 2 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Neumora Therapeutics, Inc.'s earnings high quality?
For every $1 of reported earnings, Neumora Therapeutics, Inc. (NMRA) used $0.87 of operating cash (-$206.4M OCF vs $236.9M net income). Earnings that no cash stands behind rest on accounting accruals, which cannot be repeated indefinitely. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Neumora Therapeutics, Inc. cover its interest payments?
Neumora Therapeutics, Inc. (NMRA) reported an operating loss of $241.2M against $2.0M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.